Loading company…
RAPT Therapeutics develops therapies for inflammatory diseases and cancer, including RPT904 for food allergies.
Founded in 2015 and headquartered in San Francisco, US, RAPT Therapeutics, Inc. was co-founded by Lowri Roberts and Nirav Panchmatia, with Brian Wong as CEO. Its pipeline includes RPT904, a long-acting anti-IgE antibody for food allergies, and Tivumecirnon (FLX475), a CCR4 antagonist for atopic dermatitis and asthma. In October 2019 it raised USD 149.984 mn in a PIPE from investors including TCG Crossover Management and The Column Group, and in May 2022 it raised USD 50 mn in a private placement.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in